Corticosteroids Should NOT Be Used for Intracerebral Hemorrhage
Do not administer corticosteroids (including dexamethasone) for the treatment of intracerebral hemorrhage—they provide no clinical benefit and may cause harm. This is a strong, evidence-based recommendation from multiple major guidelines.
Guideline Consensus Against Steroid Use
The prohibition against corticosteroids in ICH is remarkably consistent across all major stroke organizations:
The American Heart Association/American Stroke Association explicitly states that corticosteroids should not be administered for treatment of elevated intracranial pressure in ICH (Class III: Harm recommendation, Level of Evidence B). 1, 2
The European Stroke Organisation recommends against the use of dexamethasone in patients with acute ICH outside of research trials (Moderate quality evidence, Weak strength due to harm potential). 3
The Australian Clinical Guidelines state that corticosteroids are not recommended for management of patients with brain edema and raised intracranial pressure (Grade A, Level I evidence). 4
Evidence Base for This Recommendation
The prohibition is based on six randomized controlled trials totaling over 400 patients that consistently showed no benefit and potential harm:
Meta-analysis of four studies showed 62% mortality in the dexamethasone group versus 53% in controls (RR 1.14,95% CI 0.91-1.42), suggesting a trend toward increased death with steroids. 3
One trial showed significantly higher mortality at 21 days with dexamethasone (49%) compared to placebo (23%, P<0.05). 3
No beneficial effect was demonstrated on 6-month mortality or functional outcomes across all trials. 3
Corticosteroids increase the risk of infectious complications without providing any therapeutic benefit in acute stroke. 5
Why Steroids Don't Work in ICH (Unlike Brain Tumors)
Although dexamethasone effectively reduces vasogenic edema in brain tumors, the pathophysiology of ICH-related edema is fundamentally different:
- The edema in ICH involves both cytotoxic and vasogenic components with active bleeding and clot-related inflammation 3
- Steroids do not address hematoma expansion, the primary driver of early deterioration 6, 7
- The immunosuppressive effects increase infection risk without counterbalancing benefits 5
What TO Do Instead for Elevated ICP in ICH
When managing elevated intracranial pressure in ICH patients, use these evidence-based interventions:
For hydrocephalus with decreased consciousness:
- Place an external ventricular drain (EVD) for CSF drainage—this is reasonable and potentially lifesaving (Class IIa, Level B). 1, 2
For patients with GCS ≤8 or signs of herniation:
- Consider ICP monitoring and maintain cerebral perfusion pressure 50-70 mmHg (Class IIb, Level C). 1, 2
- Hyperosmolar therapy (mannitol or hypertonic saline) may be used for transient ICP reduction, though prophylactic use has not shown outcome benefit. 1
For cerebellar hemorrhage with deterioration:
Critical Pitfalls to Avoid
Never reflexively order steroids for ICH patients with cerebral edema, even if you would use them for a brain tumor with similar mass effect—the pathophysiology is completely different. 3, 5
Do not confuse ICH management with ischemic stroke management—corticosteroids are contraindicated in both conditions (Class III: Harm for ischemic stroke as well). 5, 9
Avoid the temptation to "try something" when ICP is elevated—steroids will not help and may increase infection risk and hyperglycemia, both of which worsen ICH outcomes. 3, 5
The Only Exception: Vasculitis-Related ICH
If the hemorrhage is secondary to autoimmune vasculitis (giant cell arteritis, primary CNS angiitis, Takayasu arteritis), then high-dose glucocorticoids ARE indicated as disease-modifying therapy. 5 However, this represents a fundamentally different clinical scenario where you are treating the underlying vasculitis, not the hemorrhage itself.